Global Clinical Specialist
An open-label, multi-center, prospective clinical trial was performed among 78 PCR-confirmed COVID-19 patients admitted to the ICU with severe or life-threatening symptoms. Convalescent plasma therapy combined with standard treatment (n = 28) was compared to standard treatment alone (n = 50), stratified by disease severity.
In combination with standard treatment, CP therapy resulted in 78% reduction of 28-day ICU mortality (HR = 0.22) compared to standard treatment alone. Also, other significant indicators of the treatment effect of CP show that this novel CP production method was effective and represents a practical solution for low and middle-income countries to produce CP locally.
After celebrating Bloodless Medicine and Surgery Day on May 16, HemoClear is attending the Annual Bloodless Medicine and Surgery Week Conference. On Thursd
HemoClear B.V. received CE Mark approval for its first-in-class, technology, the HemoClearTM autologous blood filter
As a proud sponsor, HemoClear is attending the 28th Nigerian Society of Anaesthetists Annual Scientific Conference. Dr Rosita Bihariesingh has been at the